Covid US: Just two ‘breakthrough’ infections found in 417 fully vaccinated people in NY study

Only two ‘breakthrough’ Covid infections found among 417 fully vaccinated people at a New York City university, study finds

Researchers looked at 417 employees at Rockefeller University in New York City who received both doses of the Pfizer-BioNTech or Moderna vaccines Just two people, 0.5%, tested positive more than two weeks after getting their final dose in so-called ‘breakthrough cases’   One case featured the E484K mutation, first identified in the South African and Brazilian variants, and the other the S477N mutation, seen in the NYC variantThe patients, both of whom were women, had mild infections and easily recoveredExperts say the data show that vaccines are effective but that mutations can evade the antibody response from the immune system 

Less than one percent of people at a New York City school who were fully immunized with the COVID-19 vaccine tested positive for coronavirus, a new study finds.

These so-called ‘breakthrough cases’ occur when people test positive for the virus at least 14 days after receiving their final dose of the vaccine, and which officials say is not surprising. 

Researchers found that just two people – or 0.5 percent – out of 417 employees at Rockefeller University who received both doses of the Pfizer-BioNTech and Moderna vaccines later contracted the virus.

Both patients had mild infections and easily recovered. 

The data show how well the vaccines work in real life and suggest that falling ill with COVID-19 after being fully vaccinated is very rare. 

Just two people out of 417 employees at Rockefeller University in New York City who were fully vaccinated against COVID-19 later tested positive for the virus. Pictured: Maritza Nieves (right) is tested for coronavirus antibodies in Santa Fe Springs, California, April 21 

One case featured the E484K mutation (middle), first identified in the South African and Brazilian variants, and the other the S477N mutation (right), seen in the NYC variant

One case featured the E484K mutation (middle), first identified in the South African and Brazilian variants, and the other the S477N mutation (right), seen in the NYC variant

Experts have warned that breakthrough cases will continue to occur as tens of millions of people are vaccinated across the country.

In clinical trials, the Pfizer-BioNTech’s vaccine was 95 percent effective in preventing symptomatic disease and the Moderna vaccine was 94.5 percent effective,

Next Page